GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Effect of Exchange Rate Changes

CORT (Corcept Therapeutics) Effect of Exchange Rate Changes : $0.0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Effect of Exchange Rate Changes?

Corcept Therapeutics's Effect of Exchange Rate Changes for the three months ended in Mar. 2025 was $0.0 Mil.

Corcept Therapeutics's Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 was $0.0 Mil.

Corcept Therapeutics Effect of Exchange Rate Changes Historical Data

The historical data trend for Corcept Therapeutics's Effect of Exchange Rate Changes can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Effect of Exchange Rate Changes Chart

Corcept Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Effect of Exchange Rate Changes
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Corcept Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Effect of Exchange Rate Changes Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Corcept Therapeutics Effect of Exchange Rate Changes Calculation

Effect of Exchange Rate Changes represents the effect of exchange rate changes on cash balances held in foreign currencies.

Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Effect of Exchange Rate Changes Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Effect of Exchange Rate Changes provided by GuruFocus.com. Please click on the following links to see related term pages.

Corcept Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Effect of Exchange Rate Changes
Comparable Companies
ROIV CAI TECH BPMC BBIO RVMD MDGL JAZZ HALO LEGN VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
0I3Q:UK HTD:Germany HTD:Germany
Address
101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Website
https://www.corcept.com
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Executives
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025